ArticleContact dermatitis2025
Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023.
Article in Contact dermatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing-Recommendations on Best Practice (Update 2026).Contact dermatitis · 2026Guideline
- Prevalence of Contact Allergy to Colophonium in Dermatitis Patients: A Systematic Review and Meta-Analysis.Contact dermatitis · 2026Pooled it
- Patch Test Results With the European Baseline Series, 2021/2022-Joint European Results of the ESSCAContact dermatitis · 2026Article
- Aspects of Adverse Effects of Cosmetic Products: An Invited Narrative Review.Acta dermato-venereologica · 2026Review
- Clinical Factors Associated With Current Relevance in Allergic Contact Dermatitis: Development of Predictive Models Based on Data From the Spanish Contact Dermatitis Register (REIDAC).Contact dermatitis · 2026Observational
- Ten Years of Patch Testing to Hydroperoxides of Limonene and Linalool: Prevalence, Patterns and Clinical Insights.Contact dermatitis · 2026Article
- Contact Allergy in Children in Europe: A Proposal for a Paediatric European Baseline Series.Contact dermatitis · 2026Article
- Epidemiology of Sensitivity to Nickel, Cobalt and Chromium in Israel: A Retrospective Cohort Study.Contact dermatitis · 2025Article
- Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023.Contact dermatitis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
introductionPatch test results may be influenced by age-related factors. However, there is still discordant evidence between age and patch test results.
objectivesWe aim to evaluate the patch test results reflecting skin sensitisation, their relevance and association with clinical features by age group.
methodsProspective multicentric study of all patients patch tested with the Spanish baseline series in participating centres. Age groups were pre-defined as children (0- to 11-years), adolescents (12- to 18-years), young adults (19- to 30-years), middle-aged adults (31- to 65-years) and older adults (≥66-years). Occurrence of sensitisation, relevance and clinical features were compared by age group. Factors associated with skin sensitisation were investigated with multivariate logistic regression.
resultsA total of 13 368 patients were patch-tested. Differences in positive patch test results and relevance by age were detected with the highest proportion in middle-aged adults. Age-related trend differences were found for nickel, potassium dichromate, caines, colophony, Myroxylon pereirae resin, 2-hydroxyethyl methacrylate and limonene hydroperoxide. The multivariate logistic analysis (adjusted for sex, atopic dermatitis, body location and occupational dermatitis) showed an association between the age group of 31-65 (OR: 1.41, 95% CI: 1.26-1.58) and above 66-years (OR: 1.15, 95% CI: 1.01-1.32) with a higher proportion of positive results, compared with young adults.
conclusionsPositive patch test results vary according to age, with the highest occurrence in middle-aged adults. Most haptens did not present age-related differences, reinforcing the use of baseline series regardless of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.